PDF《www.nature.com/npjschz》

ABSTRACTS OPEN Abstracts from the 5th Biennial SIRS Conference - Disclosures npj Schizophrenia (2016) 2, Article number: 16006;

doi:10.

1038/ npjschz.2016.6 Firenze Fiera Congress Center, Florence, Italy, 2C6 April,

2016 Sponsorship: Publication of this supplement was funded by the Schizophrenia International Research Society Presenter Financial Disclosure Each participant certi?es that all their (and their immediate family'

s) af?liations with or ?nancial involvement (e.g., employ- ment, consultancies, honoraria, equity ownership or stock options, grants, contracts, patents, received or pending, or royalties) with any organization or entity having a ?nancial interest in or a current or potential ?nancial con?ict with any matters related to SIRS are disclosed completely here. For purposes of disclosure, ?nancial involvement is de?ned as any income source having occurred within the last

2 years. Please note if any income source is greater than or equal to $10,000 per year or has the potential to generate that amount per year in the future (e.g. patents or royalties). Also, please note if the ?nancial involvement constitutes more than 5% of one'

s family income.* *Please note that it is the policy of the Schizophrenia International Research Society to only collect disclosure information from the presenting author. Part

1 Any Financial involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scienti?c, or medical products or companies doing business with or proposing to do business with SIRS over past

2 year, or proposing to do business in the futures (June

2013 C Present) should be listed here: Part

2 List annual income sources &

equity of $10,000 per year or greater (June

2013 C Present): Part

3 Financial involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scienti?c, or medical products or companies doing business with or proposing to do business with SIRS which constitutes more than 5% of family income (June

2013 C Present): Part

4 Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scienti?c, or medical products directly, or indirectly through a foundation, university, or any other organization (June

2013 C Present): Part

5 My primary employer is a pharmaceutical/biotech/medical device company. List company name: The following presenters had relevant ?nancial interests to disclose: Agid, Ofer: Part 1: Janssen, Advisory Board/Consultant/Speak- ing engagements;

Self. Novartis, Advisory Board/Consultant/ Speaking engagements;

Self. Otsuka, Advisory Board/Consultant/ Speaking engagements;

Self. Lundbeck, Advisory Board/Consul- tant/Speaking engagements;

Self. Part 4: Janssen, Research Contracts;

Agid O. Boehringer Ingelheim, Research Contracts;

Agid O. Neurocrine Biosciences, Research Contracts;

Agid O. Sunovion, Research Contracts;

Agid O. Albacete, Auria: Part 4: University of Barcelona, Trainee research staff grant (APIF-UB);

Auria Albacete. Anticevic, Alan: Part 1: Blackthorn, consultation &

sab;

Self. Arango, Celso: Part 1: CIBERSAM, Speaker Fee;

Self. Lundbeck, Advisory Board;

Self. Otsuka, Advisory Board;

Self. Servier, Advisory Board;

Self. Roche, Advisory Board;

Self. Takeda, Advisory Board;

Self. Roche, Advisory Board;

Self. Schering Plough, Advisory Board;

Self. Janssen Pilag, Advisory Board;

Self. Baeza Pertegaz, Inmaculada: Part 1: Otsuka, Travel support to go to a meeting;